Author

E. Khurana

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 7

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 7 Assay:bulk RNA-seq· 5 Approach:experimental assay· 4 Research Focus:cancer & tumor microenvironment· 3 Research Focus:cell type annotation· 3 Approach:statistical model· 3 Assay:whole-genome sequencing· 3 Assay:ATAC-seq· 2

Frequent Co-Authors

F. Tang· 3 shared A. Martinez-Fundichely· 2 shared A. Palladino· 2 shared C. J. Lee· 2 shared E. M. Liu· 2 shared L. E. Dow· 2 shared P. Chi· 2 shared S. Cohen· 2 shared

Activity by Year

2020-2022 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. Tang

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert tumor microenvironment and confers resistance to immunotherapy

J. Yan, Y. Chen, A. J. Patel, S. Warda, B. G. Nixon, E. W. P. Wong, M. A. Miranda-Roman, C. J. Lee, N. Yang, Y. Wang, J. Sher, E. Giff, F. Tang, E. Khurana, S. Singer, , P. Chi

This study shows that PRC2 inactivation in tumors creates an immune-desert microenvironment, leading to resistance to immunotherapy and suggests strategies to reverse this effect.

bioRxiv · May 27, 2022 · PreprintCancer Biology

Recapitulation of patient-specific 3D chromatin conformation using machine learning and validation of identified enhancer-gene targets

D. Xu, A. N. Forbes, S. Cohen, A. Palladino, T. Karadimitriou, E. Khurana

The paper develops a machine learning model to predict enhancer-gene connections from ATAC-seq and RNA-seq data, validated using multi-omics data and CRISPRi in cancer patients.

bioRxiv · Nov 16, 2021 · PreprintCancer Biology

Modeling tissue-specific breakpoint proximity of structural variations from 2,382 whole-genomes to identify cancer drivers

A. Martinez-Fundichely, A. Dixon, E. Khurana

The paper models breakpoint proximity of structural variations across 2,382 whole-genomes to identify cancer drivers by analyzing tissue-specific genomic features.

bioRxiv · Sep 27, 2021Cancer Biology

Chromatin accessibility profiles of castration-resistant prostate cancers reveal novel subtypes and therapeutic vulnerabilities

F. Tang, S. Wang, C. K. Wong, C. J. Lee, S. Cohen, J. Park, C. E. Hill, K. Eng, R. Bareja, T. Han, E. M. Liu, A. Palladino, W. Di, D. Gao, W. Abida, , E. Khurana

This study identifies four subtypes of castration-resistant prostate cancer using ATAC-seq and RNA-seq data, revealing novel therapeutic targets and classification for 370 patients.

bioRxiv · Oct 26, 2020 · PreprintCancer Biology

Developmental chromatin programs determine oncogenic competence in melanoma

A. Baggiolini, S. J. Callahan, T. Trieu, M. M. Tagore, E. Montal, J. M. Weiss, S. E. Tischfield, Y. Fan, N. R. Campbell, N. Saurat, T. Hollmann, T. Simon-Vermot, S. K. Tickoo, B. S. Taylor, R. Koche, , R. M. White

The paper shows that BRAFV600E transforming ability depends on the cell of origin's transcriptional program, with neural crest and melanoblasts being more susceptible due to higher chromatin modifying enzyme expression and ATAD2-SOX10 complex formation.

bioRxiv · May 9, 2020Cancer Biology

CNCDatabase: a database of non-coding cancer drivers

E. M. Liu, A. Martinez-Fundichely, R. Bollapragada, M. Spiwack, E. Khurana

CNCDatabase compiles non-coding cancer drivers from 32 cancer types using computational and experimental methods, providing a resource for studying their impact on gene expression and tumorigenesis.

bioRxiv · Apr 29, 2020Cancer Biology

Lineage reversion drives WNT independence in intestinal cancer

T. Han, S. Goswami, Y. Hu, F. Tang, M. P. Zafra, C. Murphy, Z. Cao, J. T. Poirier, E. Khurana, O. Elemento, J. F. Hechtman, R. Yeager, L. E. Dow

This study identifies lineage reversion as a mechanism enabling WNT-independent growth in intestinal cancer by integrating genetic alterations and extracellular signals.

bioRxiv · Jan 22, 2020Cancer Biology